Galectin Therapeutics (GALT) ( (GALT) ) has released its Q4 earnings. Here is a breakdown of the information Galectin Therapeutics (GALT) presented to its investors.
Galectin Therapeutics, a biotechnology company specializing in developing therapies targeting galectin proteins, focuses on addressing chronic liver disease and cancer. The company recently announced its financial results for 2024, highlighting significant progress in its NAVIGATE trial for belapectin, a potential treatment for MASH cirrhosis and portal hypertension. The trial showed promising results, with a notable reduction in the incidence of new varices in U.S. patients, suggesting belapectin’s potential as a therapeutic option. Financially, Galectin reported a net loss of $47.2 million for 2024, primarily due to increased research and development expenses related to the NAVIGATE trial. Despite the losses, the company secured additional funding to support ongoing operations and research. Looking ahead, Galectin is optimistic about further analyzing the NAVIGATE trial data and exploring potential partnerships to advance belapectin’s development.